Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • New Fixed dose...

    New Fixed dose combination for Hyperuricemia in Gout Patients

    Written by Dr. Kamal Kant Kohli Kohli Published On 2018-07-02T19:28:38+05:30  |  Updated On 2 July 2018 7:28 PM IST
    New Fixed dose combination for Hyperuricemia in Gout Patients

    At times target serum uric acid levels are not achieved in Gout Patients through treatment with allopurinol and diet alone In these circumstances, DUZALLO may be able to help. It is a fixed-dose oral combination of lesinurad (Zurampic, AstraZeneca) and allopurinol (multiple brands) recommended by EMA for treating hyperuricemia associated with gout. These two medicines are available in a single pill and both address under elimination and overproduction of uric acid.


    Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter whereas allopurinol reduces uric acid production by inhibiting xanthine oxidase. The drug will be available in film-coated tablets (300 mg/200 mg and 200 mg/200 mg) of Lesinurad and allopurinol.




    • DUZALLO tablets should be taken in the morning with food and water.

    • Patients should be instructed to stay well hydrated.


    Some people taking DUZALLO may have kidney problems, such as a sudden decrease in kidney function (acute kidney failure). Therefore DUZALLO should not be prescribed to patients who have severe kidney problems, have received a kidney transplant or are on dialysis.




    • Assess renal function before initiating DUZALLO.

    • Do not initiate DUZALLO if eCLcr is below 45 mL/min.

    • Discontinue DUZALLO if eCLcr persistently falls below 45 mL/min.


    The most common side effects are influenza, gastro-oesophageal reflux disease, headache and increased blood creatinine.


    DUZALLO should not be taken by patients who have

    • Severe kidney problems, have received a kidney transplant or are on dialysis

    • Have a fast breakdown of cancer cells that can lead to high uric acid (tumor lysis syndrome)

    • Have a rare inherited condition that causes too much uric acid in the blood (Lesch-Nyhan syndrome)

    • Had a skin rash or other allergic reaction after taking allopurinol.

    • Liver Problems

    • Heart Problems

    • Blood Problems: It can affect bone marrow and cause low red blood cells, white blood cells, and platelets

    • Drowsiness


    US Food and Drug Administration has already approved Duzallo for the treatment of hyperuricemia associated with gout way back in August 2017.

    DuzalloEMAFixed doseGouthyperuricemialesinuradsingle pilltumor lysis syndrome
    Source : Press Relaese

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok